Newly diagnosed glioblastoma multiforme (GBM)
- In combination with radiotherapy, then as maintenance therapy
Dose:
- Concomitant phase (with radiotherapy):
- 75 mg/m² daily for 42 days (up to 49 days) with radiotherapy
- Maintenance phase:
- Start 4 weeks after radiotherapy
- Cycle 1: OD 150 mg/m² for 5 days in a 28-day cycle
- Cycles 2–6: May increase to 200 mg/m²/day for 5 days if tolerated
Refractory anaplastic astrocytoma
- In patients whose disease has progressed after prior therapy
Dose:
- 150 mg/m²/day for 5 days every 28 days
- May increase to 200 mg/m²/day in subsequent cycles if tolerated
Capsules:5 mg, 20 mg, 100 mg, 140 mg, 180 mg, 250 mg
- Oral administration
- Take on an empty stomach (1 hour before or 2 hours after food)
- Swallow capsules whole with water
- Do not open, crush, or chew capsules
- Antiemetics may be given to reduce nausea/vomiting
Class: Alkylating agent
Mechanism of Action:
- Prodrug → Converts to MTIC (monomethyl triazeno imidazole carboxamide)
- MTIC alkylates DNA at guanine residues, leading to apoptosis of cancer cells
Pharmacokinetics:
- Half-life: ~1.8 hours
- Peak plasma: ~1 hour post-dose
- Excretion: Primarily renal (urine)
- Nausea, vomiting
- Fatigue
- Constipation
- Headache
- Loss of appetite
- Alopecia
- Hypersensitivity to temozolomide or dacarbazine
- Severe myelosuppression
- Myelosuppressive agents: Increased bone marrow suppression risk
- Live vaccines: Avoid due to immunosuppression
- Valproic acid: May alter hematologic toxicity
Drug Status
Availability | |
Pregnancy | |
Breastfeeding | |
Schedule |
BRAND NAME | STRENGTH | FORMULATION | PACK SIZE | MANUFACTURER | DISTRIBUTOR |
---|---|---|---|---|---|
Temotero | 20mg | Capsule | 5’s | Hetero Labs | Unisel Ltd |
Temotero | 100mg | Capsule | 5’s | Hetero Labs | Unisel Ltd |
Temotero | 250mg | Capsule | 5’s | Hetero Labs | Unisel Ltd |
Temozol | 100mg | Capsule | 5’s | PSM Pharma | PSM Pharma |